acetylleucyl-leucyl-norleucinal has been researched along with calpain inhibitor iii in 4 studies
| Studies (acetylleucyl-leucyl-norleucinal) | Trials (acetylleucyl-leucyl-norleucinal) | Recent Studies (post-2010) (acetylleucyl-leucyl-norleucinal) | Studies (calpain inhibitor iii) | Trials (calpain inhibitor iii) | Recent Studies (post-2010) (calpain inhibitor iii) |
|---|---|---|---|---|---|
| 321 | 0 | 53 | 187 | 0 | 76 |
| Protein | Taxonomy | acetylleucyl-leucyl-norleucinal (IC50) | calpain inhibitor iii (IC50) |
|---|---|---|---|
| Calpain-9 | Homo sapiens (human) | 1.61 | |
| Calpain-1 catalytic subunit | Homo sapiens (human) | 0.183 | |
| Procathepsin L | Homo sapiens (human) | 0.6365 | |
| Cathepsin B | Homo sapiens (human) | 0.5186 | |
| Calpain-2 catalytic subunit | Homo sapiens (human) | 0.35 | |
| Calpain-1 catalytic subunit | Sus scrofa (pig) | 0.02 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.1 | |
| Falcipain 2B | Plasmodium falciparum (malaria parasite P. falciparum) | 5 | |
| Cysteine proteinase falcipain 2a | Plasmodium falciparum (malaria parasite P. falciparum) | 5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Inomata, M; Nakamura, M; Ohno, H; Shintani-Ishida, K; Uemura, K; Yoshida, K | 1 |
| Endo, S; Kondo, M; Mourin, R; Nakazawa, T; Nishida, K; Saido, TC; Shimura, M; Yokokura, S | 1 |
| Ali, MA; Fan, X; Holt, A; Schulz, R; Stepanko, A | 1 |
| Duregotti, E; Montecucco, C; Rigoni, M; Tedesco, E | 1 |
4 other study(ies) available for acetylleucyl-leucyl-norleucinal and calpain inhibitor iii
| Article | Year |
|---|---|
Ischemia promotes calpain-mediated degradation of p120-catenin in SH-SY5Y cells.
Topics: Acetylcysteine; Calpain; Catenins; Cell Adhesion Molecules; Cell Aggregation; Cell Death; Cell Line, Tumor; Delta Catenin; Dipeptides; Humans; Ischemia; Leupeptins; Neuroblastoma; Phosphoproteins | 2007 |
Calpain-mediated degradation of G-substrate plays a critical role in retinal excitotoxicity for amacrine cells.
Topics: Amacrine Cells; Analysis of Variance; Animals; Blotting, Western; Calpain; Cell Death; Cysteine Proteinase Inhibitors; Dipeptides; Immunohistochemistry; In Situ Nick-End Labeling; Leupeptins; Mice; Mice, Inbred C57BL; Mice, Knockout; N-Methylaspartate; Nerve Tissue Proteins; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Retina | 2009 |
Calpain inhibitors exhibit matrix metalloproteinase-2 inhibitory activity.
Topics: Acrylates; Calpain; Catalysis; Cell Line; Cysteine Proteinase Inhibitors; Dipeptides; Gelatin; Humans; Inhibitory Concentration 50; Leupeptins; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Oligopeptides; Phenyl Ethers; Troponin I | 2012 |
Calpains participate in nerve terminal degeneration induced by spider and snake presynaptic neurotoxins.
Topics: Acrylates; Animals; Animals, Newborn; Calcium Signaling; Calpain; Cell Membrane Permeability; Cells, Cultured; Cytoskeleton; Dipeptides; Leupeptins; Nerve Degeneration; Neurofilament Proteins; Neurons; Neurotoxins; Phospholipases A2; Presynaptic Terminals; Rats; Rats, Wistar; Snake Venoms; Spectrin; Spider Venoms | 2013 |